Ann: FDA advises regulatory pathway for PromarkerD in US, page-32

Hi Eqz, thanks for sharing.

I’m anticipating UK engagement & PromarkerD sales prior to 2023.

The fallout of new diabetes diagnosis & substandard monitoring of diagnosed diabetics during COVID-19 lockdowns for co-morbid complications, including kidney disease, has blown out & I would not be surprised if the NHS UK takes on a test that can prevent ESRD & dialysis with multiple new treatments now available & at roughly the SAME COST of a COVID-19 PCR TEST ~$150.

Also factor in new Diabetes/CKD diagnosis in people previously healthy prior to becoming infected with COVID-19. For anyone new here, there is a lot of literature out there easy to search.

The European CE Mark for Lab tests is current until June 2023. I haven’t read this far yet, but I think that the change maybe as a result of Brexit?. PIQ onto it in the UK “Fixit”.

The Pandemic has really slowed us down in the Regulatory side of things, but now, what’s coming out of KOL & Medical Conferences is we need to fix this fast, as Chronic & Complex diseases will be the next pandemic, not just endemic.

We have the capability in PromarkerD to achieve amazing results in statistics & outcomes for Governments in Health. There is no price gouging, it’s all very fair & reasonable if you look at it within the BIG Picture.

GLTAH